- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05688241
EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases (ESPECT)
Epstein-Barr Virus (EBV) -Specific T Memory Stem Cell (Tscm) Therapy to Treat EBV- Driven Lymphomas/ Diseases
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Nina Khanna, Prof. Dr. med.
- Phone Number: +41 61 328 73 25
- Email: nina.khanna@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- University Hospital Basel, Klinik für Infektiologie und Spitalhygiene
-
Contact:
- Nina Khanna, Prof. Dr. med.
- Phone Number: +41 61 328 73 25
- Email: nina.khanna@usb.ch
-
Principal Investigator:
- Nina Khanna, Prof. Dr. med.
-
Sub-Investigator:
- Andreas Holbro, Prof. Dr. med.
-
Basel, Switzerland, 4056
- Universitäts-Kinderspital beider Basel (UKBB)
-
Contact:
- Tamara Diesch- Furlanetto, Dr. med.
-
Principal Investigator:
- Tamara Diesch- Furlanetto, Dr. med.
-
Bern, Switzerland, 3010
- Universitätsspital Bern, Klinik für Infektiologie
-
Contact:
- Urban Novak, Prof. Dr. med.
-
Principal Investigator:
- Urban Novak, Prof. Dr. med.
-
Genève, Switzerland, 1205
- Hôpitaux Universitaires de Genève, Hôpital des Enfants
-
Contact:
- Marc Ansari, Prof. Dr. med.
-
Principal Investigator:
- Marc Ansari, Prof. Dr. med.
-
Genève, Switzerland, 1211
- Hôpitaux Universitaires de Genève, Service d'Hématologie
-
Contact:
- Yves Chalandon, Prof. Dr. med.
-
Principal Investigator:
- Yves Chalandon, Prof. Dr. med.
-
Lausanne, Switzerland, 1011
- Centre hospitalier universitaire vaudois, Service et Laboratoire central d'hématologie
-
Contact:
- Michel Duchosal, Prof. Dr. med.
-
Principal Investigator:
- Michel Duchosal, Prof. Dr. med.
-
Zürich, Switzerland, 8032
- Kinderspital Zürich
-
Contact:
- Tayfun Güngör, Prof. Dr. med.
-
Principal Investigator:
- Tayfun Güngör, Prof. Dr. med.
-
Zürich, Switzerland, 8091
- University Hospital Zurich, Hämatologie
-
Contact:
- Dominik Schneidawind, PD Dr. med.
-
Principal Investigator:
- Nathan Wolfensberger, Dr. med.
-
Principal Investigator:
- Dominik Schneidawind, PD Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Patients' inclusion criteria:
- Group A: Patients with EBV driven lymphomas (e.g., NK/T-cell lymphoma), with EBV complications (e.g. HLH, CAEBV) or patients with primary immunodeficiency disorders with high risk for EBV complications (e.g. SCID) with planned allogeneic HCT
- Group B: EBV-driven PTLD that develop after a HCT or SOT
For both groups:
- All age groups
- Negative pregnancy test in female patients of childbearing potential.
- Signed written informed consent of patient or/and parents
Patients' exclusion criteria:
- Patients receiving anti-thymocyte globulin or Campath within 28 days of infusion
- Patients with active, acute GvHD grades III-IV
- Previous severe reaction to dimethylsulfoxide (DMSO)
Donors' inclusion criteria:
- EBV positive serology (VCA and Epstein-Barr nuclear antigen (EBNA) immunoglobulin G (IgG) positive)
- Detectable interferon (IFN)-y-secreting T cells (>100 SFC/10e6 PBMC) measured by Elispot to the EBV consensus peptide pool
- Suitability for blood or HCT donation meeting requirements of local institutional guidelines
- An informed consent for EBV Tscm CTL manufacturing
- Age > 18 years
Donors' exclusion criteria:
- Detectable IFN-y-secreting T-cells <100 spot-forming cell (SFC)/10e6 PBMC measured by Elispot to EBV select
- Unwilling and/or unable to donate, according to the donor center
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A: patients who undergo allogeneic HCT
Patients with EBV driven lymphomas (e.g., natural killer (NK)/T-cell lymphoma), with EBV complications (e.g.
haemophagocytic lymphohistiocytosis (HLH), CAEBV) or patients with primary immunodeficiency disorders with high risk for EBV complications (e.g.
SCID) with planned allogeneic HCT.
|
Cryopreserved cells will be thawed and infused at three time points.
Dosing will be 2x10e6 EBV CTLs per kg of body weight.
No prior lymphodepletion will be performed.
|
Experimental: Group B: patients after HCT or SOT
EBV-driven PTLD that develop after a HCT or solid organ transplantation (SOT) and show decreased response to rituximab.
|
Cryopreserved cells will be thawed and infused at three time points.
Dosing will be 2x10e6 EBV CTLs per kg of body weight.
No prior lymphodepletion will be performed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of EBV Tscm-CTL infusion assessed by number of early infusion-related events
Time Frame: up to 12 hours after first dose of EBV Tscm-CTL infusion
|
Number of early infusion-related events (early infusion-related events are clinically significant alterations of vital signs)
|
up to 12 hours after first dose of EBV Tscm-CTL infusion
|
Safety of EBV Tscm-CTL infusion assessed by number of late clinical reaction to EBV Tscm-CTLs
Time Frame: from 12 hours after first dose until 3 months after the last dose of EBV CTLs
|
Late clinical reaction to EBV Tscm-CTLs are signs of acute graft-versus-host disease (GvHD).
Acute GVHD will be graded according to the modified Glucksberg criteria.
|
from 12 hours after first dose until 3 months after the last dose of EBV CTLs
|
Assessment of feasibility to expand Tscm-enriched EBV CTLs
Time Frame: one time assessment on day 9-11 of expansion before cryopreservation (plus at least 7 days for microbiological culture)
|
Feasibility is defined as meeting the release criteria of EBV Tscm-CTL endproduct. Release criteria for the EBV Tscm-CTL follow Swissmedic Investigational Medicinal Product Dossier (IMPD). This includes viability of cluster of differentiation 3 (CD3)+ >70%, absolute CD3 count per kg of body weight per dose (≤2x10e6/kg), and a purity of CD3+ >90%. These criteria will be assessed before cryopreservation. A negative culture for bacteria and fungi for at least 7 days, endotoxin testing ≤5 EU/ml and negative result for Mycoplasma is required. |
one time assessment on day 9-11 of expansion before cryopreservation (plus at least 7 days for microbiological culture)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nina Khanna, Prof. Dr. med., Klinik für Infektiologie und Spitalhygiene, University Hospital of Basel
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Epstein-Barr Virus (EBV)
- Hematopoietic stem cell transplantation (HSCT)
- EBV-driven Lymphomas
- EBV disease
- Memory Stem Cell Therapy
- Epstein-Barr Virus-specific T Memory Stem Cell Therapy (EBV-Tscm)
- cytotoxic T-cell line (CTL)
- T memory stem cells (Tscm)
- T-cell receptor (TCR)
- post-transplant lymphoproliferative disease (PTLD)
- Wnt-β-catenin inhibition
- hematopoietic cell transplantation (HCT)
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-01210; am22Khanna
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on EBV Lymphoma
-
Baylor College of MedicineThe Methodist Hospital Research InstituteRecruitingEBV-Related Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | EBV-Related Lymphoproliferative DisorderUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedLymphoproliferative Disorders | Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | NonHodgkin Lymphoma | EBV-Related PTLD | EBV Related Lymphoma | EBV Related Hodgkin's LymphomaUnited States
-
Viracta Therapeutics, Inc.RecruitingEBV Related Non-Hodgkin's Lymphoma | Epstein-Barr Virus Associated Lymphoproliferative Disorder | EBV-Related PTLD | EBV Associated Lymphoma | EBV-Positive DLBCL, NOS | EBV Related PTCL, NOSUnited States, Spain, Italy, United Kingdom, Singapore, Taiwan, Korea, Republic of, Malaysia, Germany, Canada, Brazil, Australia, France, Hong Kong, Israel
-
Memorial Sloan Kettering Cancer CenterWithdrawnEBV Lymphomas | EBV-associated Malignancies
-
Atara BiotherapeuticsNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterCompletedEBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV LymphomaUnited States
-
Nantes University HospitalUnknown
-
Huiqiang HuangUnknownLymphoma, Extranodal NK-T-Cell | EBV
-
Atara BiotherapeuticsMemorial Sloan Kettering Cancer CenterCompletedEBV-induced Lymphomas | EBV-associated Malignancies | Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV LymphomaUnited States
-
Singapore General HospitalNational University Hospital, Singapore; National Cancer Center Singapore,... and other collaboratorsWithdrawnEBV Related Non-Hodgkin's Lymphoma | Primary CNS Lymphoma | Primary Testicular LymphomaSingapore
-
EutilexRecruitingEBV Associated Extranodal NK/T-cell Lymphoma | EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinomaKorea, Republic of
Clinical Trials on Donor-derived ex-vivo expanded EBV Tscm CTL
-
Michael Pulsipher, MDSeattle Children's Hospital; Nationwide Children's HospitalEnrolling by invitation
-
University College, LondonDeutsche Krebshilfe e.V., Bonn (Germany); European Union; The Leukemia and Lymphoma... and other collaboratorsTerminatedAcute Lymphoblastic LeukemiaUnited Kingdom, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Imperial College LondonWithdrawnAllogeneic Stem Cell Transplant | Haematological Malignancies | CD56+CD3- NK CellsUnited Kingdom
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Solving Kids' Cancer; Wade's Army; Midwest Athletes... and other collaboratorsWithdrawnOsteosarcoma | Neuroblastoma | Recurrent Neuroblastoma | Relapsed NeuroblastomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHematopoietic and Lymphoid Cell NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin LymphomaUnited States